Answer

Introduction

India is a global leader in generic medicines, supplying nearly one-fifth worldwide and 40% of U.S. demand, yet this strength rests on heavy import dependence for APIs and KSMs, exposing a critical structural contradiction.

Body

Structural Challenges in India’s Pharmaceutical Sector

• Import Dependence: India’s pharma industry relies heavily on imported APIs and KSMs, making it vulnerable to external disruptions and price shocks.
  Eg: Majority of key starting materials are sourced from abroad, especially China.
• Weak R&D Base: The sector is dominated by generics manufacturing with limited investment in original research and drug innovation.
  Eg: Indian firms focus more on reverse engineering than new drug discovery.
• Cost Trap: Competitive advantage is built on low-cost production, discouraging transition towards high-cost innovation ecosystems.
• Supply Vulnerability: Dependence on global supply chains creates risks during global crises like Covid 2019.
• Regulatory Gaps: Fragmented regulatory and policy support slows innovation and domestic capacity building.

Measures for Self-Reliance & Innovation

• Domestic Manufacturing: Strengthen indigenous production of APIs and KSMs to reduce import dependence.
  Eg: Bulk Drug Parks Scheme (₹3,000 crore) to set up mega API parks in Himachal Pradesh, Gujarat, and Andhra Pradesh.
• R&D Investment: Increase public and private investment in pharmaceutical research and innovation.
  Eg: Promotion of Research and Innovation in Pharma MedTech (PRIP) Scheme launched in 2023 to support drug discovery and new technologies.
• Policy Support: Provide targeted incentives and regulatory ease to encourage domestic production and innovation.
  Eg: Production Linked Incentive (PLI) schemes for the pharma sector.
• Supply Diversification: Reduce overdependence on specific countries by diversifying import sources and partnerships.
  Eg: Strategic sourcing from multiple global suppliers like EU, US, and ASEAN under Atmanirbhar Bharat strategy.
• Sustainable Production: Promote environmentally sustainable manufacturing of APIs and KSMs for long-term viability.
  Eg: Department of Pharmaceuticals promoting green chemistry standards and zero-liquid discharge norms in bulk drug parks

Conclusion

Bridging the gap between generic leadership and import dependence is vital for India’s health security and economic resilience. A shift towards innovation-driven, self-reliant, and sustainable pharmaceutical systems will define India’s future global competitiveness.

DOWNLOAD PDF